What's Happening?
92Bio, Inc., a biotechnology company based in Hayward, California, has commenced a Phase 1 clinical trial for NTB-928, a bispecific T-cell engaging antibody, aimed at treating platinum-resistant ovarian cancer. The trial, which is being conducted at multiple
sites in the United States, began with the first patient being dosed at START New York-Long Island under the guidance of Principal Investigator Dr. Geraldine O'Sullivan Coyne. NTB-928 is designed to selectively target and kill tumor cells overexpressing the FOLR1 antigen while sparing normal tissues. This selectivity is achieved through a dual-mechanism design that combines an affinity-tuned anti-CD3 moiety with an avidity-dependent FOLR1-binding arm. The trial will utilize a Bayesian Optimal Interval dose-escalation design to assess the safety, tolerability, and preliminary activity of NTB-928.
Why It's Important?
The initiation of this trial marks a significant advancement in the treatment of platinum-resistant ovarian cancer, a condition with limited effective treatment options. NTB-928's unique design addresses the challenge of selectivity in targeting FOLR1, an antigen overexpressed in more than 75% of ovarian cancer cases. By potentially offering a more effective and safer treatment option, this trial could pave the way for improved outcomes for patients with this difficult-to-treat cancer. The success of NTB-928 could also have broader implications for other FOLR1-positive malignancies, potentially expanding treatment options for various cancers.
What's Next?
As the trial progresses, researchers will closely monitor the safety and efficacy of NTB-928 in patients. Positive results could lead to further clinical trials and eventually, regulatory approval. The collaboration between 92Bio, START, and Northwell Health Cancer Institute highlights the importance of partnerships in advancing cancer research. If successful, NTB-928 could become a best-in-class treatment for ovarian cancer, setting a precedent for future developments in T-cell engaging therapies.
